Pharmaceutical Johnson & Johnson revealed the results of a study in which it determined that its coronavirus vaccine, which until now is a single dose, is more effective when given a booster.
In a statement issued by the company, it is assured that recipients of Janssen’s vaccine could receive a booster dose, which would increase protection against COVID-19 by nine times.
In July, the Company reported interim Phase 1/2 data published in the New England Journal of Medicine, which demonstrated that “the neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable. for eight months after immunization ”.
Because of this, the pharmacist wanted to anticipate the need for a second dose in the face of loss of immunity, so it conducted two Phase 1 / 2a studies in individuals previously vaccinated with its single-dose vaccine.
Previous data from this study determined that a booster dose of Johnson & Johnson COVID-19 vaccine rapidly and robustly increased spike-binding antibodies, “nine times greater than 28 days after primary vaccination.”
“We have established that a single injection of our COVID-19 vaccine generates strong immune responses that are long-lasting and persistent for eight months,” said Mathai Mammen, MD, Ph.D., Global Head, Research and Development at Janssen, Johnson & Johnson. .
He added that “with this new data, we also see that a booster dose of Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine.
Following the results, the Company is conducting dialogues with the US Food and Drug Administration (FDA), the US Centers for Disease Control and Prevention (CDC), the European Medicines Agency (EMA) and other health authorities regarding the Johnson & Johnson COVID-19 vaccine booster.